Chemo Regimen for Ovarian Cancer Wilmington NC

Dose-dense chemotherapy improves survival in women with advanced ovarian cancer, Japanese researchers say. Currently, paclitaxel and carboplatin given every three weeks is considered standard first-line chemotherapy for advanced epithelial ovarian cancer. However, dose-dense weekly treatment with paclitaxel is seen as a way to increase progression-free and overall survival in these patients in Wilmington, according to the new study findings.

Victor E Abraham III, MD
7655 Market St Ste A
Wilmington, NC
Specialties
Urology
Gender
Male
Education
Medical School: Temple Univ Sch Of Med, Philadelphia Pa 19140
Graduation Year: 1988

Data Provided by:
Robert Todd Bennett
(910) 763-6257
2512 Delaney Rd
Wilmington, NC
Specialty
Urology

Data Provided by:
Dr.Victor Abraham
(910) 254-9995
1098 Medical Center Drive
Wilmington, NC
Gender
M
Speciality
Urologist
General Information
Hospital: New Hanover Medical Center
Accepting New Patients: Yes
RateMD Rating
1.2, out of 5 based on 2, reviews.

Data Provided by:
Robert Todd Bennett, MD
(910) 763-6257
2512 Delaney Rd
Wilmington, NC
Specialties
Urology
Gender
Male
Education
Medical School: Finch U Of Hs/Chicago Med Sch, North Chicago Il 60664
Graduation Year: 1991

Data Provided by:
William Alton Russell, MD
(910) 763-6251
1905 Glen Meade Rd
Wilmington, NC
Specialties
Urology
Gender
Male
Languages
Spanish
Education
Medical School: Duke Univ Sch Of Med, Durham Nc 27710
Graduation Year: 1987
Hospital
Hospital: New Hanover Reg Med Ctr, Wilmington, Nc
Group Practice: Hanover Urological Assoc Pa

Data Provided by:
John Cashman, MD
(910) 763-6257
2502 Market St
Wilmington, NC
Specialties
Urology
Gender
Male
Education
Medical School: Jefferson Med Coll-Thos Jefferson Univ, Philadelphia Pa 19107
Graduation Year: 1965

Data Provided by:
Richard Joseph Mynatt, MD
1606 Physicians Dr
Wilmington, NC
Specialties
Urology
Gender
Male
Education
Medical School: Univ Of Tn, Memphis, Coll Of Med, Memphis Tn 38163
Graduation Year: 1977

Data Provided by:
Christian T Debeck
(910) 341-3389
2421 Silver Stream Lane
Wilmington, NC
Specialty
Urology

Data Provided by:
Peter Anton Zeman, MD
(910) 763-6251
1905 Glen Meade Rd
Wilmington, NC
Specialties
Urology
Gender
Male
Education
Medical School: Univ Of Nc At Chapel Hill Sch Of Med, Chapel Hill Nc 27599
Graduation Year: 2000

Data Provided by:
Roc Alan McCarthy
(910) 254-1033
2512 Delaney Rd
Wilmington, NC
Specialty
Urology

Data Provided by:
Data Provided by:

Chemo Regimen for Ovarian Cancer

Provided By:

SUNDAY, Sept. 20 (HealthDay News) -- Dose-dense chemotherapy improves survival in women with advanced ovarian cancer, Japanese researchers say.

Currently, paclitaxel and carboplatin given every three weeks is considered standard first-line chemotherapy for advanced epithelial ovarian cancer. However, dose-dense weekly treatment with paclitaxel is seen as a way to increase progression-free and overall survival in these patients, according to the new study findings.

This phase 3 study of 637 women compared the two approaches. The participants had advanced epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.

The 320 patients in the conventional regimen group received six cycles of paclitaxel (180 milligrams per meter squared; three-hour intravenous infusion). The 317 patients in the dose-dense group received paclitaxel (80 milligrams per meter squared; one-hour intravenous infusion) on days one, eight and 15. Both groups received carboplatin on day one of a 21-day cycle.

The patients in the dose-dense group had longer median progression-free survival than those in the standard treatment group (28 months versus 17 months), and longer overall survival at three years (72 percent versus 65 percent). This means that women in the dose-dense group had a 29 percent lower risk of cancer progression and a 25 percent lower risk of death, the authors explained.

Toxicity forced 113 patients in the dose-dense group and 69 patients in the conventional therapy group to stop treatment, the researchers noted. Severe anemia occurred in 214 patients (69 percent) in the dose-dense group and in 137 (44 percent) of the standard therapy group.

The survival benefits seen in the dose-dense group are rare in patients with advanced ovarian cancer, and this regimen offers a new treatment option for women with advanced epithelial ovarian cancer, concluded Dr. Noriyuki Katsumata, of the National Cancer Center Hospital in Tokyo, and colleagues.

The study, published in an upcoming print issue of The Lancet, was released online Sunday to coincide with the European Cancer Organization meeting held Sept. 20 to 24 in Berlin.

"The use of such dose-dense therapy should be decided on an individual basis together with other options for women with advanced-stage ovarian cancer," Dr. Michael A. Bookman, of the Arizona Cancer Center in Tucson, wrote in an accompanying commentary in The Lancet.

More information

The U.S. National Cancer Institute has more about ovarian cancer.

SOURCE: The Lancet, news release, Sept. 19, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com